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elderly (>/= 75 years of age) were consistently less likely to receive statins on discharge.
Conclusions: Statin use was low irrespective of CAD status and total cholesterol levels in
older patients with heart failure. These results emphasize the importance of continued
efforts to improve secondary prevention in older patients with HF and ischemic heart dis-
ease.
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Background. Peri-procedural myocardial damage after percutaneous coronary interven-
tion has been associated with higher risk of adverse events during the follow-up. Obser-
vational studies have suggested that patients (pts) pre-treated with statins have a lower
risk of peri-procedural myocardial damage after percutaneous revascularization. Aim of
our study was to confirm this hypothesis in a randomized pilot study (120 pts planned).
Methods. We present results from the first 53 enrolled pts (62±4 yrs, diabetics 23%), all
with stable angina. Pts, waiting for elective percutaneous coronary intervention, have
been randomized to atorvastatin (40 mg/day, N=26, Group A) or placebo (N=27, Group
B) from 7 days before the procedure. Myoglobin, Troponin I and CK-MB isoenzyme levels
were measured before the procedure, after 6 and 24 hours.
Results. All pts received coronary stent implantation with 100% of procedural success;
1.4 stents/pt were implanted. An increase above the threshold value in CK-MB values
was observed in 17% of pts of Group B and in 8 % of those of Group A (P=0.13), in
Troponin I levels respectively in 56% and 34% (P=0.10) and in Myoglobin values in 44%
and 23% (P=0.09). The post-procedural increase in Troponin I levels from baseline was
0.37±0.4 ng/ml in pts of Group B vs 0.14±0.3 ng/ml in those of Group A (P=0.05).
Conclusions. Preliminary data from this randomized study suggest that pre-treatment
with high doses of atorvastatin may reduce the occurrence of peri-procedural myocardial
damage after percutaneous coronary intervention with stenting. Complete data from this
study should be available at the moment of presentation.
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Background: Hypertension (HTN) and dyslipidemia (DYS) are prevalent and up to 50%
of patients with one have the other. Having both HTN and DYS results in a high risk of
cardiovascular disease (CVD). Furthermore, hypertensive and dyslipidemic goal attain-
ment is poor, with less than 10% of patients achieving both goals. The management of
these patients should therefore focus on achieving goals for both blood pressure and low-
density lipoprotein cholesterol (LDL-C) to diminish CVD risk.
Methods: Gemini is a 14-week, open-label, non-comparative, multicenter trial designed
to evaluate the efficacy and safety of atorvastatin/amlodipine single pill as initial or add-
on (integrated) therapy in the treatment of concomitant HTN and DYS. All patients had
concomitant HTN and DYS and qualified for drug therapy. In addition to lifestyle modifica-
tion, eight dosage strengths of amlodipine/atorvastatin single pill (5/10 mg, 10/10 mg, 5/
20 mg, 10/20 mg, 5/40 mg, 10/40 mg, 5/80 mg, and 10/80 mg) were titrated to improve
blood pressure and lipid control. The primary efficacy assessment was the percentage of
patients attaining both their blood pressure (Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure VI) and LDL-C (National
Cholesterol Education Program Adult Treatment Panel III) goals at endpoint.
Results: A total of 1220 patients received study medication. At baseline, mean (± SD)
systolic/diastolic blood pressure was 146.6 ± 11.0/87.9 ± 8.6 mmHg and mean LDL-C
concentration was 152.7 ± 33.2 mg/dL. At endpoint, 57.7% of patients reached both their
blood pressure and LDL-C therapeutic goals. Fifty-eight patients (4.8%) discontinued due
to adverse events (AEs). The most common AEs were respiratory tract infection (11.9%),
peripheral edema (8.8%), headache (5.4%), and myalgia (4.2%).
Conclusion: These data demonstrate that atorvastatin/amlodipine single pill is an effec-
tive and well-tolerated treatment for coexisting HTN and DYS, which helps patients better
achieve their goals for both conditions than reported historically. Atorvastatin/amlodipine
single pill should improve management of total CVD risk in patients with concomitant
HTN and DYS.
1008-191 Statin Therapy Is Associated With a 67 Percent 
Reduction in Mortality in Patients With Severe Chronic 
Heart Failure: Results From the Placebo Arm of the 
ENABLE Study
Olga Milo, Isaac Kobrin, Aline Frey, Loic Perchenet, Edo Kaluski, Nir Uriel, Alex Blatt, Zvi 
Vered, Gad Cotter, Assaf-Harofeh Medical Center, Zerifin, Israel, Actelion LTD, Allschwil, 
Switzerland
Recent small studies have demonstrated that statins therapy is correlated with improved
outcome in patients with chronic heart failure.
Methods: We examined the effect of statin therapy on the outcome of 1,000 patients with
chronic CHF NYHA IIIb or IV and echocardiographic ejection fraction < 35% enrolled in
the placebo arm of the ENABLE study. Statin therapy allocation was not randomized and
decided by each investigator, Statin therapy included simvastatin, atrovastatin, pravasta-
tin, lovastatin, cerivastatin and fluvastatin in different doses.
Results: Statin treatment was related to a 67% reduction in the risk of all cause mortality
(p<0.0001, Figure) but was not correlated with re-admissions due to heart failure. In the
present cohort statin treatment was the strongest predictor of outcome and remained an
independnt predictor in multivariate analysis.
Conclusions: Although retrospective, the results of the present study demonstrate a
strong correlation between all cause mortality and statin treatment in patients with heart
failure. This ovservation requires verification by a large prospective randomized study.
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Background: Evidence suggest that lipid-lowering treatment with statins reduces mortal-
ity and morbitity in patients with coronary artery disease. The effects of lipid-lowering
treatment during the early phase of the acute coronary syndromes are unknown. In this
study we investigated the effect of atorvastatin treatment on plasma levels of tissue plas-
minogen activator (tPA), von Willebrand factor (vWF) and factors V (fV) and VII (fVII), in
patients with unstable angina.
Methods: Forty-six patients (34 males 12 females, aged 64+/-8 years old) with unstable
ungina, were randomly divided into 2 groups and received atorvastatin 10 mg/day (n=23,
ATR group) or no statin treatment (n=23, ATR group) for 6 weeks during and after admis-
sion. Plasma levels of tPA, vWF, fV and fVII were measured at baseline, at 1 week and at
6 weeks after the admission. Levels of the above thrombotic markers were determined by
ELISA. All values are expressed as means+/-SEM.
Results: At baseline, levels of tPA, vWF, fV and fVII were not significantly different
between ATR (10.03±0.78 ng/ml, 107±6.5%, 125±7.8% and 92±4.4%) and the control
group (10.8±1.0 ng/ml, 109.3±9.2%, 126±8.1% and 90.7±6.7%, p=NS for all). After 1
week, serum levels of tPA, vWF, fV and fVII were significantly increased in control group
(13.3±1.3 ng/ml p<0.01, 127±8.5% p<0.05, 152±7.4% p<0.001 and 104±8.6% p<0.05
respectively, compared to baseline). This increase was prevented in ATR group
(12.7±1.8ng/ml, 125±9.7%, 134±5.8% and 109±7.7% respectively, p=NS compared to
baseline). However, at 6 weeks, plasma levels of tPA, vWF, fV and fVII returned to their
baseline values in both ATR group (11.2±0.9ng/ml, 91.6±8.9%, 125.3±7.8% and
94.8±6.7% respectively, p=NS for all compared to baseline) and control group
(11.4±0.95ng/ml, 98.8±10.6%, 118±6.9% and 114±31%, p=NS for all compared to base-
line).
Conclusions: During the first week of treatment, atorvastatin decreases the levels of fac-
tors V, VII, von Willebrand factor and tissue plasminogen activator in patients with unsta-
ble angina. These findings suggest that early administration of atorvastatin in patients
with unstable ungina, may be beneficial by affecting the thrombotic/fibrinolytic process.
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Overall Use 11.9 21.8
Age >/= 75 years 8.5 17.5
Prior PTCA or CABG 23.7 38.4
Total cholesterol >/= 200 mg/dL 22.6 33.5
